GLP-1 Medications May Improve Dry Eye Symptoms in Diabetes Patients
Patients with type 2 diabetes taking GLP-1 receptor agonists had significantly better tear production and tear film stability than those on other medications.
Quick Facts
What This Study Found
GLP-1 RA users had median Schirmer values of 15 mm vs. 7.5 mm and median TBUT of 10 sec vs. 5.85 sec compared to non-users.
Key Numbers
- 35 patients: 21 on GLP-1 RAs, 14 on other diabetes drugs
- Schirmer test: 15 mm (GLP-1) vs 7.5 mm (control), p=0.016
- Tear breakup time: 10 sec (GLP-1) vs 5.85 sec (control), p=0.016
How They Did This
Single-center case-control study of 35 patients with type 2 diabetes.
Why This Research Matters
Dry eye disease is very common in diabetes patients. If GLP-1 medications improve ocular surface health, this is an important additional benefit to consider.
The Bigger Picture
GLP-1 receptor agonists continue to reveal benefits beyond glucose control, potentially including anti-inflammatory effects on the ocular surface.
What This Study Doesn't Tell Us
Very small sample size (35 patients). Single center. Case-control design cannot prove causation. Groups may differ in ways not accounted for.
Questions This Raises
- ?What mechanism explains GLP-1 improvement of ocular surface health?
- ?Would these findings hold in a larger randomized trial?
Trust & Context
- Key Stat:
- 15 mm vs. 7.5 mm Schirmer test values (tear production) in GLP-1 users vs. non-users
- Evidence Grade:
- Small case-control study. Low evidence level; hypothesis-generating. Larger controlled studies needed.
- Study Age:
- Published in 2025.
- Original Title:
- GLP-1R Agonists Improve Ocular Surface Parameters in Type 2 Diabetes Mellitus.
- Published In:
- Clinical ophthalmology (Auckland, N.Z.), 19, 3829-3836 (2025)
- Authors:
- Ottonelli, Giovanni, Gaeta, Alessandro, Montericcio, Novella, Tredici, Costanza, Ortfeldt, Vittoria, Birtolo, Maria Francesca, Jaafar, Simona, Mirani, Marco, Di Maria, Alessandra
- Database ID:
- RPEP-12896
Evidence Hierarchy
Compares people with a condition to similar people without it.
What do these levels mean? →Frequently Asked Questions
Can diabetes medications help with dry eyes?
This small study suggests GLP-1 receptor agonists may improve tear production and stability in type 2 diabetes patients, but larger studies are needed to confirm.
Why do diabetes patients get dry eyes?
Diabetes causes chronic inflammation and nerve damage that can reduce tear production and quality, making dry eye disease very common in diabetic patients.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12896APA
Ottonelli, Giovanni; Gaeta, Alessandro; Montericcio, Novella; Tredici, Costanza; Ortfeldt, Vittoria; Birtolo, Maria Francesca; Jaafar, Simona; Mirani, Marco; Di Maria, Alessandra. (2025). GLP-1R Agonists Improve Ocular Surface Parameters in Type 2 Diabetes Mellitus.. Clinical ophthalmology (Auckland, N.Z.), 19, 3829-3836. https://doi.org/10.2147/OPTH.S547776
MLA
Ottonelli, Giovanni, et al. "GLP-1R Agonists Improve Ocular Surface Parameters in Type 2 Diabetes Mellitus.." Clinical ophthalmology (Auckland, 2025. https://doi.org/10.2147/OPTH.S547776
RethinkPeptides
RethinkPeptides Research Database. "GLP-1R Agonists Improve Ocular Surface Parameters in Type 2 ..." RPEP-12896. Retrieved from https://rethinkpeptides.com/research/ottonelli-2025-glp1r-agonists-improve-ocular
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.